Key Takeaways
- Clorox shares plummeted to a fresh 52-week low of $88.38, marking a 27.25% decline year-over-year
- Third-quarter fiscal 2026 earnings per share reached $1.64, surpassing Wall Street expectations by $0.10
- The company forecasts approximately 6% decline in net sales for the full fiscal year 2026
- Major investment banks including Goldman Sachs, UBS, Morgan Stanley, and Evercore ISI reduced their price targets
- Analysts express reservations about future performance despite better-than-expected quarterly earnings
Shares of Clorox (CLX) plummeted to a fresh 52-week low of $91.00 on May 1, subsequently dropping further to $88.38. The household products manufacturer has experienced a 27.25% decline over the trailing twelve months.
The sharp selloff followed the company’s April 30 release of third-quarter fiscal 2026 results and a downward revision to its annual guidance.
At first glance, the quarterly performance appeared solid. The company delivered non-GAAP earnings per share of $1.64, exceeding the consensus estimate of $1.55 by $0.10. Quarterly revenue totaled $1.67 billion, matching Wall Street projections.
However, the forward-looking guidance painted a more concerning picture. Management now anticipates net sales will contract by approximately 6% throughout fiscal year 2026. This represents a meaningful deterioration from previously communicated expectations.
The company also lowered its full-year adjusted EPS outlook to a range of $5.45 to $5.65, down from the earlier projection of $5.95 to $6.30.
Shares declined roughly 2% in the immediate aftermath of the earnings announcement.
Investment Banks Lower Price Objectives
The downward guidance revision prompted several prominent financial institutions to reduce their price targets on Clorox shares.
Goldman Sachs lowered its price objective to $83 from $94, explicitly referencing the weakened guidance as the primary rationale.
UBS decreased its target to $96 from $110 while maintaining a Neutral stance on the stock. Morgan Stanley similarly reduced its target to $97 from $110, highlighting ongoing sales headwinds in specific product segments.
Evercore ISI adjusted its price target downward to $110 from $115, noting that third-quarter performance benefited from the termination of Glad’s royalty obligations — a nonrecurring positive factor.
Valuation and Financial Health Metrics
Clorox currently trades at a price-to-earnings multiple of 15.76x, which certain market observers consider reasonable relative to earnings power. According to InvestingPro analysis, the stock appears undervalued at present price levels.
The company receives a GF Score of 68 out of 100. While profitability earns a solid 7/10 rating, growth scores just 1/10 — a red flag in the highly competitive consumer products sector.
Financial strength registers at 4/10, suggesting potential vulnerabilities in debt management and liquidity.
Management indicated that the GOJO acquisition should provide some revenue offset to the overall decline, though the company’s tone remains measured.
Insider transaction activity over the past year has been minimal — two purchase transactions and one sale, with the sale valued at approximately $1.86 million.
The company’s market capitalization currently stands at roughly $11.66 billion, representing a substantial decrease from its valuation twelve months ago.
The recent low of $88.38 marks the latest milestone in a downward trajectory that has persisted throughout the current fiscal year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
